Bio-Research.AI

#?????????? ???????????????? ???? 4.6?? ???????? # ????-23 ?????? & ?????? ?????????????????? ???????? ???????????????? #?????????????????? + ???????????????? ?????????????? ???????????????? 1 ????+ [Clinical Trials] 03/21 Johnson & Johnson’s RYBREVANT + LAZCLUZE Combo Extends Survival Over One Year in First-Line Lung Cancer [Deals] 03/21 LigaChem Bio Secures Strategic Stake and Management Rights in Iksuda Therapeutics through $25M Investment to boost ADC pipeline 03/21 Harbour BioMed and AstraZeneca partner globally to develop multi-specific antibodies with $105M investment and potential $4.575B milestones [Regulatory] 03/20 FDA approves dual-acting mAb targeting IL-23 and CD64 for Crohn's disease offering subcutaneous and intravenous induction options 03/20 FDA approves Alnylam's TTR-targeting RNAi for treating Cardiomyopathy in Transthyretin-mediated Amyloidosis patients

$1.9?? ??&?? ???????? ?????? ?????????????? ???????? ??????????????? [Clinical Trials] 03/20 Kintor Pharmaceutical Limited's hair loss treatment phase III trial meets endpoint with significant hair count increase [Deals] 03/20 Sanofi is acquiring Dren Bio, Inc.'s affiliate for a CD20-directed myeloid cell engager in a deal worth up to $1.9 billion same day : ( ↓ NASDAQ: SNY | -1.01% ) 03/19 Paratek Pharmaceuticals to acquire Optinose in a deal valued up to $330M same day : ( ↑ NASDAQ: OPTN | +56.5% ) [Regulatory] 03/20 FDA grants Orphan Drug Designation to BioInvent International AB's anti-TNFR2 antibody for treating T-cell lymphoma View the full newsletter contents for free via the link in the comments.

#??????/?????? ???????? ?????????????????? $???????? ???????? #???????????? ?????????????????? $???? ???????? #???????????????? ?????????????? ???????????????????????? $?????? ?????????????? [Clinical Trials] 03/19 Novartis reports Phase III results of AAV therapy with a 2.39-point improvement in spinal muscular atrophy trial same day : ( ↓ NYSE: NVS | -0.53% ) ( ↓ SIX: NOVN | -0.07% ) 03/19 Innovent Biologics and HUTCHMED's anti PD-1/pan VEGF inhibitor Combi significantly improve PFS in advanced renal cell carcinoma 03/19 Immunovant, Inc. phase 3 trial of anti-FcRn antibody shows 5.6 point improvement in MG-ADL scores same day : ( ↑ NASDAQ: IMVT | +7.61% ) 03/18 MaaT Pharma's phase 3 trial of microbiome therapy shows 62% gastrointestinal response rate by Day 28 [Deals] 03/19 Servier and Black Diamond Therapeutics agree on $780M deal for phase 1 RAF/RAS dual inhibitor in solid tumors same day : ( ↑ NASDAQ: BDTX | +34.52% ) 03/19 Oxford BioTherapeutics partners with Roche for new targets of cancer treatments, earning up to $36M upfront and $1B in milestones same day : ( ↓ SIX: ROG | -1.07% ) [Venture Capital] 03/19 Ampersand Biomedicines raises $65 million to advance AND-Body Therapeutics for immuno-inflammation View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 03/18 EnteroBiotix's Phase 2a trial of gut microbiome therapy in IBS-C shows improvements across key efficacy assessments over placebo 03/18 Angitia Biopharmaceuticals' recombinant therapeutic protein shows improved spinal fusion success in Phase 1/2 trial 03/17 TaiMed Biologics phase 2a study shows 94% viral suppression in HIV therapy with Combination of anti-CD4 and anti-HIV mAbs 03/17 Genmab A/S phase 1/2 trial shows 55.6% response rate for FRα-targeted TOPO1 inhibitor in ovarian cancer same day : ( ↓ NASDAQ: GMAB | -1.59% ) [Deals] 03/18 HanAll Biopharma terminates license agreement with Harbour BioMed for its myasthenia gravis antibody over trial delays [Venture Capital] 03/18 Arbor Biotechnologies raises $73.9 million to support mRNA-based gene editing therapy phase 1/2 trial for primary hyperoxaluria type 1 03/18 BioClec launches to develop Alzheimer's disease therapies with backing from Sofinnova Partners View the full newsletter contents for free via the link in the comments.

#?????????????????????? ???????????????????? ?????????? ???? ???????? ???????? ?????????????? ???????????????? $1?? ???????? #?????????????????????? ???? ?????????????????????? $1.35?? ???????? [Clinical Trials] 03/17 Orca Bio's phase 3 results show 78% disease-free survivors with regulatory T cell immunotherapy vs 38% with conventional treatment 03/17 Alexion Pharmaceuticals, Inc.'s phase III trial of PTHR1 agonist significantly normalizes serum calcium in hypoparathyroidism at 24 weeks same day : ( ↓ LSE: AZN | -1.02% ) ( ↓ NASDAQ: AZN | -0.32% ) 03/17 Scholar Rock's anti-myostatin antibody in phase 3 trial shows motor function improvement in SMA patients aged 2-21 [Deals] 03/17 AstraZeneca to acquire EsoBiotec SA for up to $1B to enhance lentivirus based in vivo cell therapy capabilities same day : ( ↓ LSE: AZN | -0.62% ) ( ↓ NASDAQ: AZN | -0.26% ) 03/17 OPKO Health, Inc. and Entera Bio Ltd. develop oral dual agonist GLP-1/glucagon peptide tablet for obesity with shared ownership and costs same day : ( ↑ NASDAQ: ENTX | +7.98% ) ( ↑ NASDAQ: OPK | +0.57% ) 03/15 ALTEOGEN Inc. and MEDIMMUNE U.K. LIMITED, a UK subsidiary of AstraZeneca, sign exclusive license deal for Hybrozyme platform-based human hyaluronidase technology in AstraZeneca's cancer drug SC formulations 03/13 ALTEOGEN Inc. enters exclusive licensing agreement with MedImmune LLC, a USA subsidiary of AstraZeneca, for subcutaneous cancer treatment [Venture Capital] 03/17 Maxion Therapeutics secures $72 million to advance antibody therapy utilizing cysteine-rich mini-proteins for inflammatory diseases into clinical trials 03/17 Curevo Vaccine raises $110 million to advance shingles vaccine into further trials [Regulatory] 03/17 GRIN Therapeutics, Inc. receives FDA Orphan Drug designation for radiprodil in GRIN-related neurodevelopmental disorder 03/17 PEP-Therapy gets FDA Orphan Drug designation for peptide-based pancreatic cancer treatment PEP-010 View the full newsletter contents for free via the link in the comments.

????'???? ???? ??????-???????????? ???????????? ???????? ???? ??????????! ??????’?? ??????????????! After attending ???????????????? last week, ??????-????????????????.???? is now at ??????-???????????? ???????????? ???????? in Milan from ?????????? ???? ???? ????! Our team—?????? ?????????? ??????, CAIO Aaron Park, Senior Product Manager JiYeong Jeong, and Data Integrity Manager Chloe Yu—is here to meet with pharmaceutical companies, biotech firms, VCs, IBs, and CROs to explore collaboration opportunities. ?? ?????????? ??????-????????????????.???? We provide ????-?????????????? ?????????????????? ????????????????????????, helping companies streamline ???????????????? ??????????????????????, ???????????????????? ??????????????????, ?????? ???????? ???????????????? with structured data and real-time insights. ?? If you’re attending ??????-???????????? ????????????, let’s set up a meeting! We’d love to discuss how our AI-driven solutions can support your work. ?? Milan, Italy ?? March 17-19, 2025 Feel free to reach out or send a meeting request. Looking forward to connecting! #BioEuropeSpring #BioEuropeSpring2025 #AIinPharma #Biopharma #LifeSciences #Networking #PharmaAI #BioResearchAI

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 03/13 Amgen's phase 3 trial shows UPLIZNA improves MG-ADL score by week 52 in AChR+ patients same day : ( ↑ NASDAQ: AMGN | +0.08% ) [Venture Capital] 03/14 Accropeutics secures $12 million to fund phase Ib trial for RIPK2 inhibitor in ulcerative colitis 03/13 Neural Therapeutics finalizes Series A financing and receives approval to list on Canadian Exchange [Regulatory] 03/14 Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy for Relapsed or Refractory Follicular Lymphoma same day : ( ↓ NYSE: BMY | -1.18% ) 03/14 FDA grants orphan drug designations to Innorna Co., Ltd.'s mRNA drug for Wilson Disease 03/14 China approves Innovent Biologics' SYCUME for treating thyroid eye disease as first IGF-1R antibody therapy 03/14 Korro Bio, Inc.'s SERPINA1 RNA editing oligo receives FDA orphan drug designation for Alpha-1 Antitrypsin Deficiency treatment 03/13 European Commission approves Rxulti for treating schizophrenia in adolescents aged 13 and older View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 03/13 Blue Earth Therapeutics' phase 1 trial shows higher radiation absorption in tumors with its radioligand therapy 03/12 GSK's ViiV Healthcare's EMBRACE phase IIb study shows 96% efficacy in maintaining suppressed HIV levels [Deals] 03/13 Mallinckrodt Pharmaceuticals and Endo Merge to Strengthen Pharmaceutical Portfolio, Expanding Treatment for Rare and Chronic Diseases 03/13 SOTIO Biotech exercises its option with Synaffix BV to advance bispecific ADC programs [Venture Capital] 03/13 Insilico Medicine secures $110 million to enhance drug pipeline and improve AI models View the full newsletter contents for free via the link in the comments.

We’re at #BioChina 2025 in Suzhou! Bio-Research.AI is excited to be here at BioChina 2025, connecting with industry leaders, innovators, and investors in the biopharma space. Over the next three days, we look forward to discussing how AI-powered intelligence is transforming pharmaceutical research, business development, and investment decision-making. If you're attending BioChina, let’s connect! We’d love to meet and explore potential synergies. Feel free to reach out or stop by to chat. ?? Suzhou, China #BioChina2025 #PharmaAI #Biopharma #LifeSciences #AIinPharma #Networking #BioResearchAI

#?????????????? ???????????? ???????????? $??.???? ???????? #?????????????? ???????? ???????? #???????????????????? ?????????????????? ?????? ???????????????? [Clinical Trials] 03/12 QurAlis's phase 1 trial of Kv7.2/7.3 ion channel opener shows decreased ALS biomarker in motor nerve excitability threshold 03/11 OSE Immunotherapeutics' phase 2 trial of neoepitope based cancer vaccine meets primary endpoint in 107 pancreatic cancer patients 03/11 YolTech Therapeutics' trial reveals over 95% serum TTR reduction with YOLT-201 low-dose administration [Deals] 03/12 Zealand Pharma and Roche to co-develop petrelintide with USD 5.6B in total payment 03/11 Ionis Pharmaceuticals, Inc. and ONO PHARMACEUTICAL CO., LTD. sign $280M deal for TMPRSS6 RNAi development rights [Regulatory] 03/12 Seikagaku Corp receives FDA complete response letter for Condoliase therapy due to manufacturing facility issues 03/11 European Commission approves telomerase inhibitor for anemia in lower-risk myelodysplastic syndromes